Novinky v biomedicínském výzkumu / Biomedical Research News

Přednášky předních světových odborníků / Lectures of international experts in biomedicine

Úterý 14. října 2025 / Tuesday October 14, 2025

Posluchárna místnost # 1.26 / Lecture hall room # 1.26, U Nemocnice 4 (přízemí vpravo / ground floor on the right)

Des Richardson

Professor Richardson is a multi-disciplinary medicinal chemist, biochemist, pharmacologist whose career has spanned medicinal chemistry, drug design/development/commercialization, cancer biology, and neurobiology. He holds the Alan Mackay-Sim Distinguished Chair of Cancer Cell Biology at Griffith University (Inaugural Chair – First Named Chair at Griffith University in its 50-year history), Nathan, Brisbane, and he is a National Health and Medical Research Council (NHMRC) of Australia Senior Principal Research Fellow. He published more than 500 articles, reviews, patents, chapters etc. with H-index over 100 and more then 45 000 citations over entire career. He was honored by the international Otto Krayer Award in Pharmacology 2022 from the American Society of Pharmacology & Experimental Therapeutics (ASPET). He is Executive Editor of BBA-General Subjects and have served on the Ed. Boards of 49 journals.

14,15 Registration

14,30 – 15,30 Redefining cancer patient care with artificial intelligence (AI) optimised anti-metastatic drugs that directly attack the major killer in cancer, tumor spread

Metastasis is the major killer in cancer that leads to 90% of cancer deaths. However, unfortunately currently in the clinics we have no drugs that specifically and directly inhibit metastasis as well as primary tumour growth and also a common form of drug resistance mediated by P-glycoprotein. The speaker will provide his experience over his 40 year career of developing innovative anti-cancer drugs that block all three of these processes. Problems with current chemotherapy, including the most advanced immunotherapies, are that they require intravenous infusions, are expensive to make, can take months for a response, and can be highly toxic. In contrast, the drugs under question are orally active, economical to prepare, can lead to rapid anti-tumor activity within days rather than months, and are specifically designed to prevent toxic off-target effects.

A case is made regarding “patient friendly” chemotherapy that is being optimised with the use of proprietary artificial intelligence (AI) to accelerate the slow drug development process and aid in the generation of this frontier class of anti-cancer drugs.